There are 2137 resources available
1274P - First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227
Presenter: Kenneth O'Byrne
Session: E-Poster Display
Resources:
Abstract
1275P - Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung cancer group
Presenter: Maria Gonzalez Cao
Session: E-Poster Display
Resources:
Abstract
1276P - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
Presenter: Jean-Baptiste Assié
Session: E-Poster Display
Resources:
Abstract
1277P - An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
Presenter: Carlo Genova
Session: E-Poster Display
Resources:
Abstract
1278P - Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Roberto Ferrara
Session: E-Poster Display
Resources:
Abstract
1279P - Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract
1280P - Analysis of ARID1A and ARID1B as potential biomarkers for NSCLC immunotherapy
Presenter: Chongbiao Huang
Session: E-Poster Display
Resources:
Abstract
1281P - The prognostic impact of tissue tumour mutational burden (TMB) in the first-line treatment of advanced non-oncogene addicted non-small cell lung cancer (NSCLC): A systematic review and meta-analysis of randomized controlled trials
Presenter: Valerio Gristina
Session: E-Poster Display
Resources:
Abstract
1282P - Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-227
Presenter: Solomon J Lubinga
Session: E-Poster Display
Resources:
Abstract
1283P - Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
Presenter: Julien Mazieres
Session: E-Poster Display
Resources:
Abstract